Form 4: Kymera COO Exercises Options, Sells Shares Under 10b5-1 Plan

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, exercised stock options and subsequently sold common stock shares as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, Inc. (KYMR), engaged in transactions involving the company's common stock.
• On March 23, 2026, Mr. Chadwick exercised options to acquire 84,400 shares of common stock at an exercise price of $29.64 per share.
• On the same date, he sold a total of 91,250 shares across multiple transactions at weighted average prices ranging from $76.7329 to $80.05 per share.
• On March 25, 2026, Mr. Chadwick exercised options to acquire an additional 24,727 shares of common stock at an exercise price of $29.64 per share.
• Also on March 25, 2026, he sold 24,727 shares at a weighted average price of $80.2586 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan established on December 10, 2025.
• Following these transactions, Mr. Chadwick directly beneficially owns 61,202 shares of common stock and 90,873 stock options.
• The stock options have a vesting schedule where 25% vested on May 22, 2024, with the remaining shares vesting in equal monthly installments over 36 months, contingent on continued employment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While insider selling can sometimes be a concern, these transactions were pre-scheduled under a 10b5-1 plan, indicating a planned financial move rather than a reaction to negative company news. The high sale prices reflect positive stock performance for the insider.

Positives

• The sales were executed at significantly higher prices (ranging from $76.7329 to $80.2586) compared to the exercise price of $29.64, indicating a substantial gain for the reporting person.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned and orderly disposition of shares rather than a reaction to immediate market conditions.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's near-term stock price appreciation, although this is not always the case with pre-scheduled plans.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology sector. These plans allow executives to sell shares over time to diversify their holdings or for personal liquidity, while mitigating concerns about insider trading by pre-scheduling transactions. The significant spread between exercise and sale prices reflects the growth in Kymera's stock value since the options were granted.

Comparison to Industry Standards

• Insider selling under a 10b5-1 plan is a standard practice for executives in publicly traded companies, including those in the biotech industry, to manage personal finances and diversify holdings without violating insider trading rules.
• The substantial profit realized by the COO from exercising options and selling shares at higher market prices is typical for executives whose companies have experienced stock appreciation, similar to what has been observed with executives at comparable growth-stage biotech firms like Arvinas Inc. (ARVN) or Relay Therapeutics, Inc. (RLAY) when their stock options mature and are exercised.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, from a routine diversification to a signal of future outlook, though the 10b5-1 plan mitigates the latter concern.
• Employees: The vesting schedule tied to continued employment reinforces the importance of executive retention.

Next Steps

• The remaining unexercised stock options will continue to vest in equal monthly installments over the remaining 36 months, subject to the reporting person's continued employment.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 plan. While the executive realized significant gains, this is a planned event and does not provide new fundamental information about Kymera Therapeutics' operational performance or future prospects that would warrant a change in investment thesis. Investors should continue to hold based on the company's core business fundamentals rather than these scheduled insider sales.

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Officer Transaction, Biotechnology, Pharmaceuticals